Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.
Disease-Free, Overall Survival Lower in Patients With CRC Treated With PE, CRS/HIPEC
Patients with stage IV colorectal cancer (CRC) had lower overall and disease-free survival if they had a pelvic exenteration (PE) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa
Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Management of HS Requires Both Coordination, Communication Between Patients and Providers
Treating pediatric and adult patients with hidradenitis suppurativa (HS) who are in socioeconomically underserved areas can be done through collaboration with the patient, their family, and other clinicians in the field.
Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments
A physician-reported outcomes survey found that physicians switched to ruxolitinib cream due to lack of effectiveness with previous atopic dermatitis (AD) treatments, and an analysis of claims data revealed the cream reduced the need for other treatments.
AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics
The American Academy of Dermatology (AAD) will host its annual conference in San Diego from March 8 to March 11, 2024, which will include sessions about Janus kinase (JAK) inhibitors, biologics, and other treatments for skin disorders.
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.